Impact of body mass index on survival and serious adverse events in advanced non-small cell lung cancer treated with bevacizumab: a meta-analysis of randomized clinical trials.
Soham ShuklaZachary BabcockLaura PizziLuigi BrunettiPublished in: Current medical research and opinion (2021)
In this analysis of clinical trial data, obesity was not associated with worse survival versus non-obese individuals in advanced NSCLC. In addition, serious adverse events were similar between patients with and without obesity.
Keyphrases
- advanced non small cell lung cancer
- weight loss
- metabolic syndrome
- body mass index
- weight gain
- insulin resistance
- clinical trial
- epidermal growth factor receptor
- type diabetes
- high fat diet induced
- bariatric surgery
- adipose tissue
- small cell lung cancer
- free survival
- physical activity
- double blind
- tyrosine kinase
- obese patients
- deep learning
- artificial intelligence
- newly diagnosed
- placebo controlled